GM-CSF and IL-4 conjugates, compositions, and methods related thereto

Patent metadata

Field	Value
Publication number	US-11053292-B2
Application number	US-201816149372-A
Country	US
Kind code	B2
Filing date	Oct 2, 2018
Priority date	Oct 23, 2012
Publication date	Jul 6, 2021
Grant date	Jul 6, 2021

Abstract

In certain embodiments, this disclosure relates to conjugates comprising a polypeptide of GM-CSF and a polypeptide IL-4. Typically, the GM-CSF and IL-4 are connected by a linker, e.g., polypeptide. In certain embodiments, the disclosure relates to isolated nucleic acids encoding these polypeptide conjugates, vectors comprising nucleic acid encoding polypeptide conjugates, and protein expression systems comprising these vectors such as infectious viral particles and host cells comprising such nucleic acids.

First claim

The invention claimed is:

1. A conjugate comprising a granulocyte macrophage colony stimulating factor (GM-CSF) polypeptide and an interleukin 4 (IL-4) polypeptide, wherein said GM-CSF polypeptide and said IL-4 polypeptide are connected by a peptide linker consisting of amino acids selected from glycine, serine, threonine, asparagine, alanine and proline, wherein the conjugate is at least 70% identical to SEQ ID NO: 8, wherein said conjugate induces proliferation of B-cells.

2. The conjugate of claim 1 wherein said GM-CSF polypeptide is located closer to the N-terminus of said conjugate relative to said IL-4 polypeptide.

3. The conjugate of claim 1 wherein said GM-CSF polypeptide comprises the amino acid sequence of SEQ ID NO: 6 and said IL-4 polypeptide comprises the amino acid sequence of SEQ ID NO: 3.

4. The conjugate of claim 1 wherein said GM-CSF polypeptide and said IL-4 polypeptide are connected by a peptide linker consisting of amino acids selected from glycine and serine.

5. The conjugate of claim 1 wherein the linker comprises repeats of serine or repeats of glycine.

6. The conjugate of claim 1 wherein the linker is 1 to 5 amino acids.

7. The conjugate of claim 1 wherein the linker is 5 to 50 amino acids.

8. The conjugate of claim 1 wherein the linker comprises GGGGS (SEQ ID NO:5).

9. The conjugate of claim 1 wherein the conjugate is at least 80% identical to SEQ ID NO: 8.

10. The conjugate of claim 1 wherein the conjugate is at least 90% identical to SEQ ID NO: 8.

11. The conjugate of claim 1 wherein the conjugate is at least 95% identical to SEQ ID NO: 8.

12. The conjugate of claim 1 wherein the conjugate is at least 97% identical to SEQ ID NO: 8.

13. The conjugate of claim 1 wherein the conjugate is at least 99% identical to SEQ ID NO: 8.

14. A pharmaceutical composition comprising a conjugate of claim 1 and a pharmaceutically acceptable excipient.

15. A vaccine comprising a conjugate of claim 1 and an antigen optionally in combination with an adjuvant.

16. A product comprising peripheral blood cells and a conjugate of claim 1 .

17. An isolated nucleic acid encoding the conjugate of claim 1 .

18. A recombinant vector comprising the nucleic acid of claim 17 .

Assignees

• Univ Emory
• Childrens Healthcare Atlanta Inc

Inventors

• Galipeau Jacques
• Deng Jiusheng

Classifications

• A61K40/4271

  Melanoma antigens · CPC title

• A61K40/24

  Antigen-presenting cells [APC] · CPC title

• A61K40/13

  B-cells · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/57

  Skin; melanoma · CPC title